PMID- 3261587
OWN - NLM
STAT- MEDLINE
DCOM- 19880913
LR  - 20190718
IS  - 0004-3591 (Print)
IS  - 0004-3591 (Linking)
VI  - 31
IP  - 8
DP  - 1988 Aug
TI  - Subacute cutaneous lupus erythematosus. Clinical, serologic, immunogenetic, and 
      therapeutic considerations in seventy-two patients.
PG  - 1007-13
AB  - We studied 72 patients with subacute cutaneous lupus erythematosus (SCLE). 
      Forty-nine of the patients had been part of an earlier study. The cutaneous 
      disease was primarily annular in 17 patients, papulosquamous in 48, and a 
      combination in 7. Although the major feature of SCLE is nonscarring, 
      non-atrophy-producing lesions, scarring discoid lesions were observed in 21 
      patients. Thirty-six patients fulfilled criteria for systemic lupus 
      erythematosus. Cytoplasmic antibodies were present in only 22 patients. However, 
      in the group of 23 patients recently analyzed, 13 of 22 tested had anti-Ro (SS-A) 
      and/or anti-La (SS-B). HLA-DR3 was present in 22 of 59 patients. Neither anti-Ro 
      (SS-A) nor HLA-DR3 correlated with any clinical finding. Forty-seven patients 
      have had continued activity of their disease, but in most patients, the disease 
      has been controlled with sunscreens, topical and intralesional corticosteroids, 
      and oral hydroxychloroquine. A broad spectrum of systemic lupus 
      erythematosus-associated phenomena can occur in patients with SCLE. The disease 
      is frequently easily controlled, and may become quiescent. This subset of lupus 
      patients is less distinctive than has been previously suggested.
FAU - Callen, J P
AU  - Callen JP
AD  - University of Louisville School of Medicine, Kentucky.
FAU - Klein, J
AU  - Klein J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Arthritis Rheum
JT  - Arthritis and rheumatism
JID - 0370605
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Antibodies, Antinuclear)
RN  - 0 (HLA-D Antigens)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (HLA-DR3 Antigen)
RN  - 0 (SS-A antibodies)
RN  - 0 (SS-B antibodies)
RN  - 0 (Sunscreening Agents)
RN  - 4QWG6N8QKH (Hydroxychloroquine)
SB  - IM
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Adult
MH  - Antibodies, Antinuclear/*analysis
MH  - Female
MH  - HLA-D Antigens/*analysis
MH  - HLA-DR Antigens/*analysis
MH  - HLA-DR3 Antigen
MH  - Humans
MH  - Hydroxychloroquine/therapeutic use
MH  - *Lupus Erythematosus, Cutaneous/diagnosis/drug therapy/immunology
MH  - Male
MH  - Sunscreening Agents/therapeutic use
EDAT- 1988/08/01 00:00
MHDA- 1988/08/01 00:01
CRDT- 1988/08/01 00:00
PHST- 1988/08/01 00:00 [pubmed]
PHST- 1988/08/01 00:01 [medline]
PHST- 1988/08/01 00:00 [entrez]
AID - 10.1002/art.1780310811 [doi]
PST - ppublish
SO  - Arthritis Rheum. 1988 Aug;31(8):1007-13. doi: 10.1002/art.1780310811.